GLP-1 weight loss plateaus: What actually works vs. TikTok fixes

What did @drkameshaglp1 actually say?

The creator, who claims to be down "40 plus pounds" on compounded semaglutide after 22 weeks, offered three plateau-busting strategies: eat more calories, address constipation, and talk to your doctor about a dose increase. She framed low calorie intake as a possible cause of stalled weight loss and said constipation can make the scale look like it isn't moving. She also said she personally tried to stay on "the lowest dose as I could for as long as I could" before asking for an increase.

Worth noting: the creator refers to GLP-1 medications throughout as "GOP 1," which is clearly a speech artifact and not a medical claim. She also mentions "compound and some McGlutide," which appears to be compounded semaglutide. She does not claim this is equivalent to brand-name Wegovy or Ozempic, which is the right call.

Does the science back this up?

Partly, yes. The idea that inadequate calorie intake can stall weight loss on GLP-1 medications has some physiological basis, though the evidence is more nuanced than the video suggests. The constipation point is real but limited in scope. The dose escalation advice is the most clinically grounded claim she makes.

GLP-1 receptor agonists suppress appetite significantly, and some patients undereat to the point where metabolic adaptation and lean mass loss can become concerns. Lean mass loss during rapid caloric restriction can reduce resting metabolic rate, which may contribute to plateau (Muller et al., 2016, Obesity Reviews). However, calling this a simple "not eating enough" problem oversimplifies what is actually a complex metabolic response. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed that semaglutide's weight loss effects do plateau over time as the drug reaches its biological ceiling, and that effect is independent of constipation or calorie math.

On constipation: GI side effects including constipation affect roughly 24% of semaglutide users in clinical trials (Davies et al., 2021, Lancet). It does add temporary scale weight. That is accurate. But this is not a meaningful driver of true fat loss plateaus.

What did they get wrong (or right)?

She got the constipation point technically right but framed it in a way that could mislead. A few pounds of GI backup is not a weight loss plateau. It is water and stool weight. Conflating the two could give people false hope that their plateau will resolve once they have a bowel movement, when the real issue may be metabolic adaptation or a need for dose adjustment.

The "not eating enough" framing deserves more skepticism. The research on reverse dieting and metabolic adaptation in GLP-1 users is not robust enough to make this a reliable general recommendation. Some patients genuinely undereat on these drugs and lose lean mass, which matters. But telling a broad TikTok audience to "sneak in extra calories" without clinical guidance is risky. Overeating is still a common problem even on GLP-1 medications, and the right calorie target varies by individual.

What she got right: the advice to talk to a doctor before escalating dose is responsible. She did not recommend a specific dose, she did not suggest self-adjusting, and she framed the conversation as one that belongs with a prescriber. That is exactly the right message.

What should you actually know?

Weight loss plateaus on GLP-1 medications are well-documented and have multiple causes. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed that weight loss typically plateaus around 60-65 weeks on semaglutide 2.4mg, and this plateau is largely driven by the drug reaching its pharmacological ceiling, not by diet failures. That is a fundamentally different explanation than what this video offers.

Genuine plateaus on GLP-1 therapy may reflect the need for dose escalation, a switch in medication class, reassessment of dietary quality (not just quantity), or evaluation of other metabolic factors like thyroid function or sleep quality. None of these are captured by the three-step approach in the video.

• If you are on compounded semaglutide, be aware that compounded drugs are not FDA-approved and are not confirmed to be bioequivalent to brand-name semaglutide. Do not assume they behave identically.
• Persistent plateaus lasting more than 4-8 weeks warrant a clinical conversation, not a TikTok checklist.
• Protein intake during GLP-1 therapy matters more than total calories for preserving lean mass. Volpi et al. and multiple obesity medicine guidelines recommend 1.2-1.6g of protein per kg of body weight during active weight loss.